

## Amendments to the Claims

### **1-18. (Cancelled)**

**19. (Previously presented)** An aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester.

**20. (Previously presented)** The aqueous liquid preparation according to claim 19, wherein the alkyl aryl polyether alcohol type polymer is tyloxapol;

wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.5 w/v %; and

wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is selected from a range of about 0.01 to about 0.5 w/v %.

**21. (Previously presented)** The aqueous liquid preparation according to claim 20, wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.

**22. (Previously presented)** The aqueous liquid preparation according to claim 21, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is selected from a range of about 0.05 to about 0.2 w/v %.

**23. (Previously presented)** The aqueous liquid preparation according to claim 22, wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v % to about 0.3 w/v %.

**24. (Previously presented)** The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

**25. (Previously presented)** The aqueous liquid preparation according to claim 24, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**26. (Previously presented)** The aqueous liquid preparation according to claim 25, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**27. (Previously presented)** The aqueous liquid preparation according to claim 26, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**28. (Previously presented)** The aqueous liquid preparation according to claim 27, wherein the pH is from about 7 to about 9.

**29. (Previously presented)** The aqueous liquid preparation according to claim 28, wherein the pH is from about 7.5 to about 8.5.

**30. (Previously presented)** The aqueous liquid preparation according to claim 27, wherein said liquid preparation is in the form of an eye drop.

**31. (Previously presented)** The aqueous liquid preparation according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

**32. (Previously presented)** The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.3 w/v %.

**33. (Previously presented)** The aqueous liquid preparation according to claim 32, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**34. (Previously presented)** The aqueous liquid preparation according to claim 33, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**35. (Previously presented)** The aqueous liquid preparation according to claim 34, wherein said liquid preparation is in the form of an eye drop.

**36. (Previously presented)** The aqueous liquid preparation according to claim 31, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**37. (Currently amended)** The aqueous liquid preparation according to claim 36, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**38. (Previously presented)** The aqueous liquid preparation according to claim 37, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**39. (Previously presented)** A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof.

**40. (Previously presented)** A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative.